Restarting GLP-1 Medication: What Prescribers Need to Know About Re-Titration

Key takeaways

Between 36% and 47% of patients who discontinue GLP-1 therapy reinitiate within a year. Restart is not an edge case — it is a routine clinical scenario.

After more than four weeks off treatment, both semaglutide and tirzepatide are effectively cleared. Full re-titration from the lowest dose is recommended.

No validated dose equivalence exists between semaglutide and tirzepatide. Patients switching drugs should always start at the lowest dose.

Patients who restart GLP-1 therapy after a gap retain significant cardiovascular benefit (12% MACE reduction), though less than those on continuous treatment (18%).

NHS specialist weight management re-referral exclusions of up to 24 months mean many restart patients will present through private or pharmacy-led pathways.

This is not a rare scenario

A patient who was stable on semaglutide 2.4 mg walks into your pharmacy. They stopped three months ago — supply issues, a holiday, cost concerns, or simply life getting in the way. Now they want to restart. What do you prescribe?

If you are prescribing GLP-1 receptor agonists for weight management, this is a conversation you will have regularly. The data bears this out. A 2025 retrospective cohort study of 125,474 adults published in JAMA Network Open found that 46.5% of patients with type 2 diabetes and 64.8% without discontinued GLP-1 therapy within a year. Of those who stopped, 47.3% and 36.3% respectively reinitiated treatment within 12 months [1]. A separate Cleveland Clinic analysis of 7,938 patients found that 20% restarted their original medication and a further 27% switched to a different GLP-1 agent [2].

The restart patient is not an outlier. They are a substantial proportion of your caseload. Yet restart protocols receive remarkably little attention in prescriber education, and no randomised controlled trial has specifically studied optimal re-titration strategies. What follows is the best available evidence, drawn from SmPC guidance, pharmacokinetic principles, and real-world data.

Semaglutide (Wegovy): SmPC restart guidance

The Wegovy SmPC is the most explicit of the two drugs on restart. If a patient has missed two or more consecutive weekly doses, the SmPC recommends considering reinitiation of the full dose escalation schedule (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, each step maintained for four weeks). The label states that re-escalation “may reduce the occurrence of gastrointestinal symptoms associated with reinitiation of treatment” [3].

The pharmacokinetics reinforce this. Semaglutide has a half-life of approximately seven days. After five half-lives — roughly 35 days — less than 3% of steady-state drug concentration remains. A patient who has been off semaglutide for more than five weeks is, from a pharmacokinetic standpoint, effectively drug-naive.

Full re-titration from 0.25 mg to the maintenance dose of 2.4 mg takes 16 to 20 weeks.

Tirzepatide (Mounjaro): SmPC restart guidance

The Mounjaro SmPC is less prescriptive about restart. It addresses missed doses — if fewer than four days (96 hours) have elapsed since the scheduled dose, the patient should take it; if more than four days, they skip to the next scheduled dose — but does not provide an explicit multi-week restart protocol [4].

Expert consensus fills the gap. Tirzepatide has a shorter half-life than semaglutide (approximately five days versus seven), meaning five half-lives are reached in roughly 25 days. After a gap exceeding four weeks, most clinicians recommend full re-titration from the starting dose of 2.5 mg.

The full tirzepatide titration schedule (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, each step four weeks minimum) takes up to 20 weeks to reach maximum dose. Tirzepatide does offer more maintenance dose options than semaglutide, giving prescribers greater flexibility during re-escalation.

Gap duration thresholds: a practical framework

No RCT has established definitive thresholds for when re-titration is required. The table below reflects SmPC guidance, pharmacokinetic clearance data, and expert consensus [3][4][5].

Gap duration	Semaglutide action	Tirzepatide action	Rationale
Less than 2 weeks (1 missed dose)	Resume at current dose on next scheduled day	Resume at current dose on next scheduled day	Significant circulating drug remains
2 to 4 weeks (2+ missed doses)	SmPC recommends considering re-escalation	Clinical judgement; consider reducing dose	GI tolerance partially lost
More than 4 weeks	Full re-titration from 0.25 mg	Full re-titration from 2.5 mg	Drug effectively cleared after 5 half-lives

In practice, some prescribers restart at a mid-range dose when the gap is short and the patient previously tolerated the drug well. This is not supported by SmPC guidance and carries increased gastrointestinal risk. Published case reports describe adverse outcomes when patients resumed at their previous high dose after a gap, including complications requiring hospital readmission [5].

The conservative approach — re-titrate from the lowest dose after any gap exceeding four weeks — is the safest recommendation you can make.

Drug switching: no validated equivalence

The Cleveland Clinic data shows that 27% of patients who discontinue switch to a different medication rather than restarting the same one [2]. The most common pattern is switching between semaglutide and tirzepatide.

There is no validated dose equivalence between the two drugs. They have different receptor profiles (GLP-1 only versus dual GIP/GLP-1), different pharmacokinetic characteristics, and different titration schedules. Approximate clinical equivalences circulate informally — semaglutide 1.0 mg is sometimes mapped to tirzepatide 5 mg, for instance — but these are not regulatory-endorsed and should not be used to determine a starting dose on the new drug [6].

When a patient switches from one GLP-1 agent to another, always initiate from the lowest dose. This applies regardless of what dose they were stable on with the previous drug. Time the switch by completing the last dose of the outgoing drug, waiting one full dosing interval (one week), and then starting the new drug.

A study published in Endocrine Practice found that patients switching from stable GLP-1 RA therapy directly to tirzepatide 5 mg (rather than 2.5 mg) experienced improved glycaemic outcomes with acceptable GI adverse events over 12 weeks [7]. However, this was a single-arm study and does not establish that skipping the starting dose is appropriate for all patients, particularly those restarting after a gap.

Gastrointestinal side effects on restart

GI symptoms — nausea, vomiting, diarrhoea, constipation, and abdominal discomfort — are the most common reason patients cite for discontinuing GLP-1 therapy. It is reasonable for patients to ask whether they will experience the same symptoms again.

The honest answer is: probably, but manageably so.

GI tolerance to GLP-1-mediated gastric slowing develops over weeks and is lost during a treatment gap. The longer the gap, the more complete the loss [8]. If a patient re-titrates properly from the lowest dose, GI side effects on restart should be broadly comparable to their initial titration experience — not worse, not better. If they skip the re-titration and restart at a higher dose, GI effects can be significantly more severe due to the absence of accumulated tolerance.

Patients who originally discontinued because of GI intolerance warrant particular attention. They may benefit from an even more conservative re-titration schedule, with longer intervals between dose escalation steps, and proactive counselling about dietary modification and timing of meals relative to injection days [8][9].

Cardiovascular considerations

Emerging data from a Washington University/VA study published in March 2026 examined cardiovascular outcomes in patients who interrupted and then restarted GLP-1 therapy [10]. The findings are clinically relevant for restart counselling:

Continuous GLP-1 use over three years: 18% reduction in major adverse cardiovascular events (MACE)
Restarted after a gap: 12% MACE reduction (partial recovery of benefit)
Six-month interruption then restart: 4-8% increased cardiovascular risk versus continuous use
Two-year gap before restart: 22% increased risk versus continuous use

These findings suggest that treatment gaps leave a lasting “scar” on cardiovascular benefit, even after restarting. This is not grounds for alarm — a 12% MACE reduction is still clinically meaningful — but it does reinforce the case for minimising unnecessary treatment interruptions and restarting promptly when a gap has occurred.

Safety concern: self-reinitiation at previous dose

Perhaps the most important safety issue prescribers should be aware of is patients who restart at their previous maintenance dose without clinical guidance. A patient who was stable on semaglutide 2.4 mg or tirzepatide 15 mg and has leftover pens may attempt to resume at that dose after a multi-week gap.

This is dangerous. Without the accumulated GI tolerance that develops during titration, a full maintenance dose can cause severe nausea, vomiting, and dehydration. The SmPC re-titration guidance exists precisely to prevent this. Any patient presenting to restart should be asked directly whether they have already attempted to resume on their own, and at what dose.

UK-specific prescribing context

NHS pathways. NICE TA875 (semaglutide) and TA1026 (tirzepatide) do not explicitly address restart eligibility after discontinuation. In practice, NHS specialist weight management services typically impose a 24-month re-referral exclusion period after a patient has left the pathway early or disengaged. Exceptions may be granted for documented reasons such as surgery, bereavement, or caring responsibilities [11].

Some integrated care boards impose additional restrictions. South Yorkshire ICB, for example, limits patients to one course of tirzepatide up to 24 months. This means an NHS patient who discontinues tirzepatide may not be eligible for a second NHS-funded course.

Private and pharmacy pathways. There is no waiting period for restart through private clinics, online prescribing services, or pharmacist independent prescribers. A new clinical assessment is required regardless of setting — GPhC standards mandate this even if the patient was previously stable on the medication [12]. The prescriber should review the patient’s treatment history, reason for discontinuation, current weight and comorbidities, and any intervening health changes before reissuing a prescription.

The practical implication: many restart patients will present through private or pharmacy-led pathways, either by choice or because the NHS re-referral exclusion directs them there.

Restart checklist for prescribers

When a patient presents wanting to restart GLP-1 therapy, the following assessment covers the key clinical and practical considerations:

Looking ahead

The evidence base for GLP-1 restart protocols is built largely on pharmacokinetic reasoning, SmPC missed-dose guidance, and expert consensus. No randomised controlled trial has directly compared restart strategies — this is a significant gap in the literature. As the proportion of restart patients grows (and it will), prescribers who develop structured, evidence-informed restart pathways will deliver better outcomes and retain more patients through what is an inherently fragile transition.

References

Truveta Research. Discontinuation and Reinitiation of Glucagon-Like Peptide 1 Receptor Agonists. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2024.56345
Cleveland Clinic. What Happens When Patients Stop Taking GLP-1 Drugs: New Cleveland Clinic Study Reveals Real-World Insights. Cleveland Clinic Newsroom. March 2026. Link
Novo Nordisk. Wegovy (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium. Link
Eli Lilly. Mounjaro (tirzepatide) Summary of Product Characteristics. European Medicines Agency EPAR. Link
Missed Doses, Missed Opportunities: Clinical Implications of GLP-1 RA Treatment Interruptions. PMC. Link
Switching Between GLP-1 Receptor Agonists: Expert Consensus. PMC. Link
Switching to Tirzepatide 5 mg from Stable GLP-1 RA Therapy. Endocrine Practice. Link
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists. PMC. Link
Gastrointestinal Adverse Events Associated with GLP-1 Receptor Agonists. Nature International Journal of Obesity. 2025. Link
Washington University School of Medicine. Stopping GLP-1 Drugs Can Quickly Erase Cardiovascular Benefits. WashU Medicine News. March 2026. Link
NICE. Technology Appraisal TA875: Semaglutide for Managing Overweight and Obesity. National Institute for Health and Care Excellence. Link
General Pharmaceutical Council. Standards for Pharmacy Professionals. GPhC. Link

Cadence Health provides structured GLP-1 patient support for pharmacies, clinics, and prescribers — including patients restarting treatment after a gap. If you are building a weight management service and want to see how pharmacokinetically-timed support works in practice, book a demo.